GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipca Laboratories Ltd (NSE:IPCALAB) » Definitions » Capital Expenditure

Ipca Laboratories (NSE:IPCALAB) Capital Expenditure : ₹0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Ipca Laboratories Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Ipca Laboratories's cash flow for capital expenditures for the three months ended in Mar. 2025 was ₹0 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0.00 Mil.

Ipca Laboratories Capital Expenditure Historical Data

The historical data trend for Ipca Laboratories's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipca Laboratories Capital Expenditure Chart

Ipca Laboratories Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,615.50 -4,789.50 -4,944.70 -4,112.90 -7,755.70

Ipca Laboratories Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ipca Laboratories Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipca Laboratories Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipca Laboratories Ltd (NSE:IPCALAB) » Definitions » Capital Expenditure
Comparable Companies
BOM:532296 BOM:543064 BOM:532331 BOM:540222 BOM:543635 BOM:506943 NSE:GLAND BOM:544210 BOM:532300 BOM:540596 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
524494:India
Address
125, Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Website
https://www.ipca.com
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.

Ipca Laboratories Headlines

No Headlines